Angiotensinogen is a precursor of the multifunctional octapeptide hormone, angiotensin II. We have isolated the overlapping clones containing angiotensinogen gene locus from C57BL/6 mouse genomic DNA library and analyzed them by restriction enzyme mapping.
HE sequential processing of circulating angiotensinogen by renin (EC 3. 4. 23. 15) and angiotensin-converting enzyme (ACE) (EC 3. 4. 15. 1) to yield the octapeptide angiotensin II (AII) is initiated by the release of the enzyme renin, primarily from the kidney.1) AII formed in this way has multiple diverse physiological effects on adrenal function, systemic blood pressure regulation, neurotransmitter synthesis and release, neovascularization, induction of drinking and ovulation.
2) The diverse cellular roles of AII are presumably all mediated by interactions between the effector peptide and its specific receptors for the peptide in the plasma membrane of the target organs including blood vessel, kidney, adrenal, brain, anterior pituitary, uterus, ovary and heart.3) In addition to the circulating renin-angiotensin system, accumulating data reveal that components of the system also exist in these target organs and their presence is the result of tissue-specific gene expressions. Thus, an emerging concept is that AII may be produced locally in multiple tissues, independent of the circulating system, and that local synthesis of AII may be a significant autocrine or paracrine modulator of tissue function. 4) The production of transgenic mice by pronuclear microinjection has provided an especially powerful new tool not only for studying the regulation of gene expression in mammalian development, but also for studying the pathogenesis of human diseases as well as for developing and testing new therapies.5) Recently we have, therefore, generated the transgenic mice carrying the human renin6)-9) and angiotensinogen10) genes and analyzed tissue-and cell-specific expression of these transgenes. Although the recombinational reactions of such transfer of the foreign gene into mice are usually nonhomologous, many cell types also possess the enzymatic machinery required for homologous recombination. The homology-dependent recombination between chromosomal DNA and exogenous sequences is referred to as gene targeting, and it offers an additional dimension to transgenic technology.11) Gene targeting permits the transfer of genetic alterations created in vitro to precise sites within the cellular genome. Particularly, mouse blastocyst-derived embryonic stem (ES) cells that are pluripotent provide us with an excellent opportunity to investigate gene function in the context of the developing and adult animals. This strategy of creating animals with specific genomic changes has immense potential in medicine and in furthering our understanding of the genetic control of mammalian development.
In the present study, as a first contribution to the analysis of mutants carrying lesions within the renin-angiotensin system, we have cloned the mouse angiotensinogen gene from C57BL/6, and characterized its gene structure and promoter activity. gene as a probe (Fig. 2 ). In the adult mouse, angiotensinogen was expressed predominantly in the liver as a single RNA 2kb in size. It was also detectable in a variety of tissues, such as brain, kidney, submandibular gland, ovary and heart. Dzau et al19) have used RNA blot hybridization to compare the expression of the angiotensinogen gene in mouse and rat. The difference between mouse and rat is that angiotensinogen mRNA is detectable in testis and submandibular gland of mouse, but not in either tissue of rat. It was of interest, therefore, to compare the 5'-flanking regions of the mouse and rat20) genes, since it is well established that most regulatory sequence elements lie in the 5'-flanking region of eukaryotic genes. Alignment of the mouse and rat 5'-flanking region (Fig. 3) revealed a typical TATA box beginning at comparable positions in both genes. Two other features shown in the alignment are particular noteworthy.
First, a region extending from nucleotide +22 to -207 in the mouse gene exhibits striking sequence similarity (90% identical) to its rat homolog. On the other hand, a further comparison to the promoter region of the human angiotensinogen gene15) reveals the lower homology (47% identical) in the region. Second, the mouse gene contains a large deletion located between nucleotide positions -209 and -210, where the rat gene contains 28 consecutive thymidine residues.20) One hypothesis arising from this comparison is that these various conserved domains and/or the multiple insertions and deletions could be important in determining the observed pattern of tissue-or species-specific expression of the angiotensinogen gene.
A convenient approach to study control of gene expression in eukaryotic cells and to identify DNA sequences functioning as cis-acting transcriptional signals is to fuse a predetermined DNA segment upstream to the coding sequence of the bacterial enzyme CAT. These constructs are then introduced Jpn. Heart J. J anuary 1992 Fig. 3 . Alignment of the 5'-nontranscribed regions of the mouse (m.), rat (r.), and human (h.) angiotensinogen genes. Optimal alignments were generated using the HARPLT2 program (SDC-GENETICS).
Dashed lines, indicating hypothetical deletions, were placed in the sequences to achieve maximum homology. The numbers indicate the nucleotide positions of the mouse sequence upstream from the putative start site of transcription (+1). A colon among the three species sequences indicates an identity among their nucleotides. The TATA box is denoted by the horizontal line.
into cultured cells by transfection, and expression can be measured as CAT enzymatic activity. Therefore, we initiated an in vitro study to identify functionally important domains in the 5'-flanking region of the mouse angiotensinogen gene. DNA sequences containing the 5'-flanking region of the mouse angiotensinogen gene (425 nucleotides) were fused to the CAT gene. The hybrid CAT gene was introduced into different cell lines, and the transient expression of the CAT gene, mediated by the promoter activity of the angiotensinogen gene fragment, was measured.
The results in Fig. 4 showed that the 5'-flanking sequences of the angiotensinogen gene exhibit the promoter activity in hepatoma HepG2 cells and embryonic kidney 293 cells, but not in cervical carcinoma HeLa cells. This suggested the presence of a functional and cell type-specific promoter within this region tested. 
DISCUSSION
Analysis of the mouse angiotensinogen gene structure is an important first step toward analyzing the function and mechanism which regulates its expression. The genomic organization of C57BL/6 mouse angiotensinogen gene predicted from the restriction enzyme mapping is almost identical to that of the balb/c gene, whose structure is very similar to that of the other species.15),21) By genomic Southern blot analysis, Clouston et al22) found that a major difference between the structures of C57BL/6 and balb/c angiotensinogen genes is that an intracisternal A-particle (IAP) gene family is cells by the insertion of an IAP gene in the 5' end of the c-mos coding region .26) However, it is unclear whether the IAP sequence of the C57BL/6 angiotensinogen gene has an ability to activate the gene expression as a regulatory element.
We have determined the sites of synthesis of mouse angiotensinogen by screening for the presence of its mRNA in a variety of tissues. The angiotensinogen mRNA was detected in the liver, kidney, submandibular gland, brain and heart. Additionally, Dzau et al19) have found that the angiotensinogen mRNA is present in the adrenal and testis in CD-1 mouse, but Clouston et al27) demonstrated that its testicular mRNA is absent in balb/c and A/J mice. Although the former authors described only the presence of angiotensinogen mRNA in the heart of CD-1 mouse19) and the latter authors established that both the endogenous angiotensinogen gene and the transgenic mini-balb/c angiotensinogen gene are expressed in the transgenic mouse heart of Swiss strain,27) no data are available for the expression of cardiac angiotensinogen gene in normal mouse. Thus, our result is the first report of the cardiac expression of the normal mouse angiotensinogen gene.
The traditional concept of the renin-angiotensin system is a circulating endocrine system whose components are secreted by different organs, i.e., renin from the kidney, angiotensinogen from liver and angiotensin-converting enzyme from lung. Recently, there is increasing recognition that the reninangiotensin system exerts its modulatory influences on circulating homeostasis not only through its circulating components, but also through generation of these components at a local level in various tissues. Especially in the heart, the biochemical and molecular biological identification of renin, angiotensinogen, AII and its specific receptor has supported the existence of the intrinsic renin-angiotensin system. Although ACE-like activity was reported to be higher in atria than in ventricles,28) it has been suggested to be different from the enzyme present in lung with regard to a number of parameters, such as isoelectric point, noncovalent cation requirements and substrate specificity.29) Instead of the known pathway of angiotensin production through ACE, recent studies have suggested that alternative pathways leading to the formation of AII are active in the heart30) and demonstrated that the major cardiac AII-forming enzyme is chymase,31) a serine protease, with an ability to convert angiotensin I to AII specifically. The identification of heart chymase adds a new dimension to the cardiac renin-angiotensin system, because this chymase potentially allows for the formation of AII without an inactivation of other regulatory peptides. Therefore the paracrine and autocrine functions of cardiac angiotensin have received a great deal of attention for several reasons as follows: First, the cardiac angiotensin may influence coronary vascular tone and therefore blood flow. Second, in addition to its vasoconstricting effect, angiotensin has also shown a positive inotropic property and may contribute to the regulation of cardiac contractility.32) The third speculative function of the angiotensin is in the cardiac cell development.
Since it has been reported that AII induces hypertrophy, not hyperplasia, of cultured aortic smooth muscle cells,33) it is a logical extension to speculate that angiotensin may be involved in the cardiac hypertrophy.
In contrast, of particular interest is the observation that constitutive expression of the introduced proto-oncogene c-myc in the transgenic mouse during development results in enhanced hyperplastic growth of the heart.34) In fact, Naftilan et al35) have provided evidence that AII can induce c-myc mRNA in vascular smooth muscle cells. Although there is no direct evidence at present time, it would be likely that angiotensin plays a role in cardiac hyperplasia through the c-myc gene activation.
It is well established that tissue culture cells transfected with recombinant DNA can express cloned genes if the regulatory sequences are present.
Comparison of the 5'-flanking sequences of the rat, human and mouse angiotensinogen genes shows that these regions contain several identifiable promoter elements, including TATA box at positions around -30 bp relative to the putative start site of transcription.
Clouston et al27) identified that the 750-bp 5'-flanking sequence of the balb/c mouse angiotensinogen gene is a minimal promoter, being sufficient to confer steroid hormones and bacterial endotoxin inducibility, on a mini-gene construct containing an internal deletion of much of its coding region introduced into the genome of Swiss mice. Our previous result regarding the human angiotensinogen promoter analysis showed that the 1.3-kb 5'-flanking sequences can function in a cell type-specific fashion.15) Brasier et al36) also found that there are multiple cis-acting DNA regulatory elements, in the 1.6-kb 5'-flanking region of the rat angiotensinogen gene, mediating its hepatic gene expression. In the present study, we have demonstrated that the DNA flanking sequences which contain 425 nucleotides of the mouse angiotensinogen gene appear to be responsible for its cell type-specific transcription in HepG2 and 293 cells. It has been proposed that the cell-and species-specific activity of flanking DNA sequences may be due to interactions with trans-acting factors.37) The specific gene activity could, therefore, be determined by the presence or absence of trans-acting factors that interact with the regulatory sequences to activate or repress transcription.
Although we cannot rule out that other sequences present in and around the mouse angiotensinogen gene in its native chromosomal location have regulatory functions, we suspect that the Jpn. Heart J. J anuary 1992
425-bp 5'-flanking sequences are the best locations for detecting DNA elements involved in cell-and species-specific transcriptional control of the angiotensinogen gene. We can now ask if this type of control is mediated through the enhancer, the proximal element, or through as yet unidentified sequences. In summary, we have cloned the C57BL/6 mouse angiotensinogen gene and localized the functional promoter to the 5'-flanking region of the gene. As mentioned in the introduction of this literature, the gene-targeting strategy has been widely used to transfer mutations created in vitro to specific loci in mouse ES cells. Thus, we believe that the characterization of the angiotensinogen gene structure and the creation of mice with defined mutations within the gene should facilitate further understanding of the in vivo function of angiotensin.
